XML 22 R7.htm IDEA: XBRL DOCUMENT v3.20.4
Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Operating activities    
Net loss $ (19,306,672) $ (16,414,159)
Adjustments to reconcile net loss to net cash used in operating activities:    
Impairment loss 34,169 0
Depreciation 466,009 494,232
Stock-based compensation expense 1,764,804 884,943
Change in fair value of derivative financial instruments—warrants 280,844 (28,188)
Release of clinical trial funding commitment 1,100,415 703,327
Changes in operating assets and liabilities:    
Other assets (246,656) (54,778)
Accounts receivable and unbilled receivable (116,978) (35,725)
Prepaid expenses and other current assets (1,100,364) 115,459
Operating lease right-of-use assets 320,248 302,491
Accounts payable and accrued expenses 1,276,166 1,455,336
Operating lease liabilities (856,845) (776,806)
Other liabilities 69,898 86,368
Net cash used in operating activities (16,314,962) (13,267,500)
Investing activities    
Capital expenditures (211,880) (67,622)
Net cash used in investing activities (211,880) (67,622)
Financing activities    
Proceeds from sale of common stock, preferred stock and warrants, net of expenses of $7,507,123 and $158,678 respectively 112,299,949 8,817,772
Costs related to the clinical trial funding commitment (7,500) (40,000)
Proceeds from exercise of warrants 24,871,586 3,299,509
Proceeds from exercise of options 148,196 0
Borrowings under note payable 305,000 0
Repayments of note payable (305,000) 0
Net cash provided by financing activities 137,312,231 12,077,281
Net change in cash and cash equivalents 120,785,389 (1,257,841)
Cash and cash equivalents—Beginning of period 10,195,292 11,453,133
Cash and cash equivalents—End of period 130,980,681 10,195,292
Supplementary disclosure of cash flow activity:    
Cash paid for taxes 800 800
Supplemental disclosure of non-cash investing and financing activities:    
Preferred stock dividend payable on Series A Convertible Preferred Stock 24,240 24,240
Series C Convertible Preferred Stock    
Supplemental disclosure of non-cash investing and financing activities:    
Deemed dividend recognized on beneficial conversion features of convertible preferred stock 0 268,269
Common stock, Series C Convertible Preferred Stock and warrants issued in connection with clinical trial funding commitment, net of discount of $235,640 0 1,675,000
Common stock issued upon conversion of Convertible Preferred Stock 0 33
Series D Convertible Preferred Stock    
Supplemental disclosure of non-cash investing and financing activities:    
Deemed dividend recognized on beneficial conversion features of convertible preferred stock 601,767 0
Common stock, Series C Convertible Preferred Stock and warrants issued in connection with clinical trial funding commitment, net of discount of $235,640 2,300,000 0
Common stock issued upon conversion of Convertible Preferred Stock 155 0
Series E Convertible Preferred Stock    
Supplemental disclosure of non-cash investing and financing activities:    
Deemed dividend recognized on beneficial conversion features of convertible preferred stock 2,664,717 0
Common stock issued upon conversion of Convertible Preferred Stock $ 86 $ 0